Eupraxia Pharmaceuticals Inc., has received approval from regulators in Australia and Canada to broaden its Phase 1b/2a RESOLVE trial, focusing on EP-104GI as a potential remedy for eosinophilic esophagitis (EoE). This decision comes after promising findings from initial low-dose cohorts, indicating potential efficacy, safety, and sustained impact of EP-104GI.

Dr. James Helliwell, Eupraxia's CEO, expressed enthusiasm for the trial's progress, highlighting positive patient responses and sustained duration of effect. The company's DiffuSphere™ technology facilitates higher dosing, potentially enhancing treatment effectiveness and patient outcomes. Notably, encouraging data from the low-dose cohorts prompted the trial's expansion, aiming for potential registration by 2025.

The protocol amendment, cleared by health authorities in Australia and Canada, involves higher dose levels of EP-104GI, increased participant enrollment, and extended follow-up periods. This expansion aims to further evaluate safety, efficacy, and treatment duration. Additionally, the trial will include esophagogastroduodenoscopy procedures to comprehensively assess treatment impact.

EoE, characterized by esophageal inflammation and associated swallowing difficulties, affects a significant number of individuals, necessitating effective treatment options. The RESOLVE trial, leveraging Eupraxia's innovative technology, aims to address this unmet medical need by assessing EP-104GI's potential as a therapeutic solution.

In summary, Eupraxia's RESOLVE trial expansion represents a significant advancement in developing EP-104GI as a potential therapy for EoE. It builds upon promising clinical data to progress towards future registration trials, addressing a critical medical challenge.

 

Source: prnewswire.com

Report Abuse